Pancreatic Tumor Progression Associated With CD133 Overexpression
Authors:
- Ching-Chieh WengCWChing-Chieh Weng
- Kung-Kai KuoKKKung-Kai Kuo
- Huei-Ting SuHSHuei-Ting Su
- Pi-Jung HsiaoPHPi-Jung Hsiao
- Yu-Wen ChenYCYu-Wen Chen
- Deng-Chyang WuDWDeng-Chyang Wu
- Wen-Chun HungWHWen-Chun Hung
- Kuang-Hung ChengKCKuang-Hung Cheng
- 1 March 2016
- journal article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 45 (3) , 443-457
Abstract
The aim of this study was to investigate the role of CD133 in pancreatic ductal adenocarcinoma malignancy and its involvement in epidermal growth factor receptor (EGFR) signaling. The effects of CD133 overexpression on cell proliferation, migration, invasiveness, and angiogenesis were investigated in the human pancreatic ductal adenocarcinoma cell line AsPC-1 in vitro and severe combined immunodeficiency xenografts in vivo. AsPC-1 cells overexpressing CD133 (AsPC-1 CD133 cells) had elevated cell proliferation, tumorigenesis, cell cycle progression, adhesion, migration, and angiogenesis. AsPC-1 CD133 cells displayed increased survival during treatment with chemotherapeutic agents. CD133 overexpression resulted in decreased EGF expression, increased telomerase reverse transcriptase expression, and increased Akt phosphorylation. Immunoprecipitation assays and immunofluorescent labeling studies revealed that CD133 physically interacts with EGFR. The EGFR inhibitor gefitinib was shown to have potent anti-CD133 activity, decreasing the CD133-induced migration of AsPC-1 CD133 cells. Knockdown of CD133 was also observed to inhibit AsPC-1 CD133 cell proliferation, migration, and invasion. Our results indicate that CD133-induced cancer stem cell activity may arise from enhanced telomerase reverse transcriptase expression and CD133 ligand-independent EGFR activation to exhibit the cancer stem cell phenotype, promoting cancer stem cell proliferation independent of cytokines, with high metastatic potential and the development of chemoresistance.Keywords
This publication has 29 references indexed in Scilit:
- Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cellsProceedings of the National Academy of Sciences, 2013
- Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell DifferentiationCell Reports, 2012
- The Stem Cell Marker CD133 Associates with Enhanced Colony Formation and Cell Motility in Colorectal CancerPLOS ONE, 2010
- CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancerBritish Journal of Cancer, 2008
- Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55α Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to AktJournal of Biological Chemistry, 2008
- Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic CancerCell Stem Cell, 2007
- Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor CellsGastroenterology, 2007
- A Perivascular Niche for Brain Tumor Stem CellsCancer Cell, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Pancreatic cancer biology and geneticsNature Reviews Cancer, 2002